* | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
Schedule 13G | ||
CUSIP No. 64065J106 | PAGE 2 of 6 |
(1) | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON OPKO Health, Inc. 75-2402409 | |||||||
(2) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨ | |||||||
(3) | SEC USE ONLY | |||||||
(4) | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | (5) | SOLE VOTING POWER | ||||||
5,063,841 | Common Shares* Series A Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series B Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series C Warrants to purchase up to 2,466,576 Common Shares (see Item 4)* | |||||||
(6) | SHARED VOTING POWER | |||||||
0 | ||||||||
(7) | SOLE DISPOSITIVE POWER | |||||||
5,063,841 | Common Shares* Series A Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series B Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series C Warrants to purchase up to 2,466,576 Common Shares (see Item 4)* | |||||||
(8) | SHARED DISPOSITIVE POWER | |||||||
0 | ||||||||
(9) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||||
5,063,841 | Common Shares* Series A Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series B Warrants to purchase up to 2,054,794 Common Shares (see Item 4)* Series C Warrants to purchase up to 2,466,576 Common Shares (see Item 4)* | |||||||
(10) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ | |||||||
(11) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||||
9.9% | ||||||||
(12) | TYPE OF REPORTING PERSON CO |
Schedule 13G | ||
CUSIP No. 64065J106 | PAGE 3 of 6 |
(a) | Name of Person filing: OPKO Health, Inc. (the “Company”) |
(b) | Address of Principal Business Office: 4400 Biscayne Blvd., Miami, FL 33137 |
(c) | Citizenship: Delaware |
(a) | ¨ | Broker or dealer registered under Section 15 of the Act; | |
(b) | ¨ | Bank as defined in Section 3(a)(6) of the Act; | |
(c) | ¨ | Insurance Company as defined in Section 3(a)(19) of the Act; | |
(d) | ¨ | Investment Company registered under Section 8 of the Investment Company Act of 1940; | |
(e) | ¨ | Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E); | |
(f) | ¨ | Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F); | |
(g) | ¨ | Parent Holding Company, in accordance with Rule 13d- 1(b(ii)(G); | |
(h) | ¨ | Savings Associations as defined in Section 3(b) of the Federal Deposit Insurance Act; | |
(i) | ¨ | Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940; | |
(j) | ¨ | Group, in accordance with Rule 13d-1(b)(1)(ii)(J). |
Schedule 13G | ||
CUSIP No. 64065J106 | PAGE 4 of 6 |
(a) | Amount beneficially owned: |
* | This number includes 5,054,794 Common Shares held by the Company and 9,047 Common Shares issued in exchange for the exercise of certain fully vested stock options held by the Company. |
** | The Company holds (i) 2,054,794 Series A Warrants, (ii) 2,054,794 Series B Warrants, and (iii) 822,192 Series C Warrants (collectively, the “Warrants”) which were issued pursuant to a public offering in which the Company purchased 2,054,794 Series A Units at a per unit price of $1.46. Each Series A unit consisted of (i) one Common Share, (ii) one Series A Common Share purchase warrant, (iii) one Series B Common Share purchase warrant, and (iv) one 0.40 Series C warrant to purchase a Series C Unit comprised of one Common Share, one Series A Warrant and one Series B Warrant. Each Warrant is exercisable upon issuance and each Warrant contains terms that prohibit the Company from exercising any portion of such Warrants if doing so would result in the Company (together with certain affiliates) beneficially owning more than 9.99% of the number of Common Shares of the Issuer outstanding immediately after giving effect to its exercise of such portion (the “9.99% blocker”). The amount of Common Shares set forth in sub clauses (a) and (c) above and on Rows (5), (7) and (9) of the cover page for the Company show the number of Common Shares that would be issuable upon full exercise of the Warrants as of November 17, 2017 (without giving effect to certain anti-dilution provisions contained in the Warrants), giving effect to such 9.99% blocker. The percentage of Common Shares owned by the Company, excluding the Warrants is 4.8%. |
*** | The percentage set forth in sub clause (b) above and on Row 11 of the cover page for the Reporting Person is based on 104,616,910 Common Shares issued and outstanding a reported by the Issuer to the Company. |
Schedule 13G | ||
CUSIP No. 64065J106 | PAGE 5 of 6 |
Schedule 13G | ||
CUSIP No. 64065J106 | PAGE 6 of 6 |
DATED: February 14, 2018 | /s/ Kate Inman | |||||
OPKO Health, Inc. | ||||||
By: Kate Inman, General Counsel, Secretary |